鱼跃医疗
(002223)
| 流通市值：257.81亿 | | | 总市值：274.28亿 |
| 流通股本：9.42亿 | | | 总股本：10.02亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,370,366,154.18 | 7,955,022,614.76 | 6,544,895,742.68 | 4,658,967,431.03 |
| 营业收入 | 2,370,366,154.18 | 7,955,022,614.76 | 6,544,895,742.68 | 4,658,967,431.03 |
| 二、营业总成本 | 1,866,982,526.48 | 6,616,589,598.1 | 5,187,824,391.82 | 3,579,183,683.09 |
| 营业成本 | 1,180,164,309.42 | 3,930,042,261.81 | 3,249,593,235.42 | 2,312,457,767.92 |
| 税金及附加 | 22,326,740.29 | 76,397,429.33 | 62,066,173.32 | 44,346,091.89 |
| 销售费用 | 402,815,941.57 | 1,763,462,079.41 | 1,232,547,528.65 | 812,432,951.98 |
| 管理费用 | 110,547,207.98 | 475,517,451.17 | 339,196,375 | 219,566,853.95 |
| 研发费用 | 158,685,705.74 | 570,145,985.28 | 444,570,559.97 | 295,071,504.55 |
| 财务费用 | -7,557,378.52 | -198,975,608.9 | -140,149,480.54 | -104,691,487.2 |
| 其中:利息费用 | - | 5,997,356.94 | - | - |
| 其中:利息收入 | 48,107,693.6 | 249,182,104.77 | 172,420,498.89 | 120,572,298.5 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,271,021.41 | 34,149,903.34 | 34,974,001.74 | 32,692,343.07 |
| 资产处置收益 | -371,380.78 | 1,281,395.38 | 1,067,120.71 | 1,249,796.19 |
| 资产减值损失(新) | 141,611.71 | -29,634,938.18 | -9,624,422.43 | -9,524,443.91 |
| 信用减值损失(新) | -30,246,861.9 | -3,837,303.57 | -24,045,999.88 | -26,682,106.57 |
| 其他收益 | 26,114,710.86 | 359,928,878.71 | 325,588,275.08 | 309,347,676.27 |
| 四、营业利润 | 501,292,729 | 1,700,320,952.34 | 1,685,030,326.08 | 1,386,867,012.99 |
| 加:营业外收入 | 445,484.44 | 26,290,665.47 | 1,863,016.25 | 1,463,787.54 |
| 减:营业外支出 | 336,039.97 | 42,119,422.16 | 2,560,464.88 | 1,230,372.8 |
| 五、利润总额 | 501,402,173.47 | 1,684,492,195.65 | 1,684,332,877.45 | 1,387,100,427.73 |
| 减:所得税费用 | 72,190,934.45 | 200,355,944.78 | 218,034,227.66 | 187,433,372.28 |
| 六、净利润 | 429,211,239.02 | 1,484,136,250.87 | 1,466,298,649.79 | 1,199,667,055.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 429,211,239.02 | 1,484,136,250.87 | 1,466,298,649.79 | 1,199,667,055.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 428,328,475.91 | 1,481,794,880.13 | 1,466,043,552.13 | 1,202,704,408.78 |
| 少数股东损益 | 882,763.11 | 2,341,370.74 | 255,097.66 | -3,037,353.33 |
| 扣除非经常损益后的净利润 | 410,114,212.99 | 1,168,613,796.79 | 1,169,266,533.55 | 913,718,165.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.43 | 1.48 | 1.47 | 1.2 |
| (二)稀释每股收益 | 0.43 | 1.48 | 1.47 | 1.2 |
| 八、其他综合收益 | -21,770,602.63 | 98,208,788.57 | -25,254,882.74 | -42,485,052.57 |
| 归属于母公司股东的其他综合收益 | -20,954,061.59 | 95,069,868.13 | -28,877,933.06 | -46,393,514.36 |
| 九、综合收益总额 | 407,440,636.39 | 1,582,345,039.44 | 1,441,043,767.05 | 1,157,182,002.88 |
| 归属于母公司股东的综合收益总额 | 407,374,414.32 | 1,576,864,748.26 | 1,437,165,619.07 | 1,156,310,894.42 |
| 归属于少数股东的综合收益总额 | 66,222.07 | 5,480,291.18 | 3,878,147.98 | 871,108.46 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-25 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |